FOR
IMMEDIATE RELEASE
Contact Information:
Eidogen’s Target Informatics Platform™ pilot
licensed
by Boehringer Ingelheim
Pasadena, CA (March 30, 2004) - Eidogen, Inc.,
a biotechnology company committed to developing
the finest computational drug discovery platforms,
announces today that Boehringer Ingelheim has
agreed to pilot license Eidogen’s Target
Informatics Platform™ (TIP™) software.
TIP is the industry’s first structural
informatics enterprise software solution that
successfully bridges the gap between bioinformatics
and cheminformatics. Eidogen’s Pilot
License program offers prospective customers
the opportunity to use TIP for a limited period
at a reduced cost. “This is another significant
milestone for Eidogen; it demonstrates that
major pharmaceutical companies see real value
in the in-silico chemogenomics discovery strategy
enabled by TIP,” said Derek Debe, Eidogen’s
Co-Founder and CEO. “We are excited to
be working with Boehringer Ingelheim.”
About Eidogen, Inc.
Eidogen is a Pasadena, California-based company
committed to delivering the finest computational
drug discovery platforms ever developed. Eidogen’s
Target Informatics Platform (TIP) supports new
and truly collaborative research in target prioritization,
lead discovery, and lead optimization, enabling
drug discovery organizations to effectively attack
their druggability, selectivity, toxicity, and
reduced market exclusivity problems. Please visit
www.eidogen.com to learn more.
About Boehringer Ingelheim
The Boehringer Ingelheim Corporation is one of
the world’s 20 leading pharmaceutical
companies. Headquartered in Ingelheim, Germany,
it operates globally with 156 affiliates in
44 countries and more than 32,000 employees.
Since it was founded in 1885, the family-owned
company has been committed to researching,
manufacturing and marketing novel products
of high therapeutic value for human and veterinary
medicine.
In 2002, Boehringer Ingelheim posted net sales
of 7.6 billion euro while spending about one
fifth of net sales in its largest business segment
Prescription Medicines on research and development.
Please visit www.boehringer-ingelheim.com to
learn more.
# # #
|
|
